Division of Endo International PLC
Latest From Par Pharmaceutical
Study finds unintended consequences of FDA initiative requiring manufacturers of unapproved drugs to obtain approval or remove them from the market but FDA says study does not consider broad impact of the initiative.
With Endo's announcement July 6 that it will conform with FDA's request to remove Opana ER from the market, the specialty firm's prospects seem tied even more tightly to its generics business.
There has been $150bn worth of merger and acquisition activity since 2012 in the generic medicines arena, yet the sector is more fragmented than it was five years ago. CEOs and analysts from the generics sector believe that investor-propelled moves towards greater consolidation have been thwarted by the market agility of smaller companies. And now the cost of M&A has burdened major generics firms with debt.
Glenmark Pharmaceuticals reported overall growth in the fourth quarter of 2016-17, but investors bludgeoned the company’s shares on concerns around the slow traction of generic Zetia in the US and a sharp decline in earnings on a sequential basis.
- Controlled Release
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Par Pharmaceutical Cos. Inc.
- Par Pharmaceutical Holdings Inc.
- Qualitest Pharmaceuticals
- Pharmaceutical Resources Inc.
- North America
- Parent & Subsidiaries
- Endo International PLC
- Senior Management
- Paul V Campanelli, Pres.
- Contact Info
Phone: (845) 573-5500
One Ram Ridge Rd.
Chestnut Ridge, NY 10977
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.